Cargando…

Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors

BACKGROUND: Pancreatic ductal adenocarcinoma is a particularly challenging malignancy characterized by poor responsiveness to conventional chemotherapy. Although this tumor frequently overexpresses or possesses constitutively activated variants of IGF-IR and EGFR/Her-2, clinical trials using inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Urtasun, Nerea, Vidal-Pla, Anna, Pérez-Torras, Sandra, Mazo, Adela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403908/
https://www.ncbi.nlm.nih.gov/pubmed/25886138
http://dx.doi.org/10.1186/s12885-015-1249-2
_version_ 1782367404270026752
author Urtasun, Nerea
Vidal-Pla, Anna
Pérez-Torras, Sandra
Mazo, Adela
author_facet Urtasun, Nerea
Vidal-Pla, Anna
Pérez-Torras, Sandra
Mazo, Adela
author_sort Urtasun, Nerea
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma is a particularly challenging malignancy characterized by poor responsiveness to conventional chemotherapy. Although this tumor frequently overexpresses or possesses constitutively activated variants of IGF-IR and EGFR/Her-2, clinical trials using inhibitors of these receptors have failed. ErbB receptors have been proposed as one mechanism involved in the resistance to IGF-IR inhibitors. Therefore, combined treatment with inhibitors of both IGF-IR and ErbB receptors would appear to be a good strategy for overcoming the emergence of resistance. METHODS: Sensitivity of cells to NVP-AEW541 and lapatinib in single or combination treatment was assessed by MTT or WST-8 assays in a panel of human pancreatic cancer cell lines and cancer stem cells. Tumorspheres enriched in cancer stem cells were obtained from cultures growing in non-adherent cell plates. The effects on cell signalling pathways were analyzed by Western blot. RESULTS: We found that combined treatment with the IGF-IR and EGFR/Her-2 inhibitors NVP-AEW541 and lapatinib, respectively, synergistically inhibited pancreatic cancer cell growth. Analysis at molecular level argued in favor of cross-talk between IGF-IR and ErbBs pathways at IRS-1 level and indicated that the synergistic effect is associated with the total abolishment of Akt, Erk and IRS-1 phosphorylation. Moreover, these inhibitors acted synergistically in tumorsphere cultures to eliminate cancer stem cells, in contrast to their resistance to gemcitabine. CONCLUSIONS: Taken together, these data indicate that simultaneous blockade of IGF-IR and EGFR/Her-2 using NVP-AEW541 and lapatinib may overcome resistance in pancreatic cancer. Thus, the synergy observed with this combined treatment indicates that it may be possible to maximize patient benefit with the appropriate combination of currently known anticancer agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1249-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4403908
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44039082015-04-21 Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors Urtasun, Nerea Vidal-Pla, Anna Pérez-Torras, Sandra Mazo, Adela BMC Cancer Research Article BACKGROUND: Pancreatic ductal adenocarcinoma is a particularly challenging malignancy characterized by poor responsiveness to conventional chemotherapy. Although this tumor frequently overexpresses or possesses constitutively activated variants of IGF-IR and EGFR/Her-2, clinical trials using inhibitors of these receptors have failed. ErbB receptors have been proposed as one mechanism involved in the resistance to IGF-IR inhibitors. Therefore, combined treatment with inhibitors of both IGF-IR and ErbB receptors would appear to be a good strategy for overcoming the emergence of resistance. METHODS: Sensitivity of cells to NVP-AEW541 and lapatinib in single or combination treatment was assessed by MTT or WST-8 assays in a panel of human pancreatic cancer cell lines and cancer stem cells. Tumorspheres enriched in cancer stem cells were obtained from cultures growing in non-adherent cell plates. The effects on cell signalling pathways were analyzed by Western blot. RESULTS: We found that combined treatment with the IGF-IR and EGFR/Her-2 inhibitors NVP-AEW541 and lapatinib, respectively, synergistically inhibited pancreatic cancer cell growth. Analysis at molecular level argued in favor of cross-talk between IGF-IR and ErbBs pathways at IRS-1 level and indicated that the synergistic effect is associated with the total abolishment of Akt, Erk and IRS-1 phosphorylation. Moreover, these inhibitors acted synergistically in tumorsphere cultures to eliminate cancer stem cells, in contrast to their resistance to gemcitabine. CONCLUSIONS: Taken together, these data indicate that simultaneous blockade of IGF-IR and EGFR/Her-2 using NVP-AEW541 and lapatinib may overcome resistance in pancreatic cancer. Thus, the synergy observed with this combined treatment indicates that it may be possible to maximize patient benefit with the appropriate combination of currently known anticancer agents. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1249-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-04 /pmc/articles/PMC4403908/ /pubmed/25886138 http://dx.doi.org/10.1186/s12885-015-1249-2 Text en © Urtasun et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Urtasun, Nerea
Vidal-Pla, Anna
Pérez-Torras, Sandra
Mazo, Adela
Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title_full Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title_fullStr Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title_full_unstemmed Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title_short Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors
title_sort human pancreatic cancer stem cells are sensitive to dual inhibition of igf-ir and erbb receptors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403908/
https://www.ncbi.nlm.nih.gov/pubmed/25886138
http://dx.doi.org/10.1186/s12885-015-1249-2
work_keys_str_mv AT urtasunnerea humanpancreaticcancerstemcellsaresensitivetodualinhibitionofigfiranderbbreceptors
AT vidalplaanna humanpancreaticcancerstemcellsaresensitivetodualinhibitionofigfiranderbbreceptors
AT pereztorrassandra humanpancreaticcancerstemcellsaresensitivetodualinhibitionofigfiranderbbreceptors
AT mazoadela humanpancreaticcancerstemcellsaresensitivetodualinhibitionofigfiranderbbreceptors